NASDAQ: CDAKCodiak Biosciences Inc Stock
$0.81+0.06 (+8%)
Updated Feb 3, 2023
CDAK Price
$0.81
Fair Value Price
$2.86
Market Cap
$29.68M
52 Week Low
$0.30
52 Week High
$7.15
P/E
-1.26x
P/B
0.76x
P/S
0.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$34.07M
Earnings
-$17.42M
Gross Margin
100%
Operating Margin
-43.46%
Profit Margin
-51.1%
Debt to Equity
2.45
Operating Cash Flow
-$67M
Beta
1.53
Next Earnings
Mar 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A
CDAK Overview
Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. The company has developed a platform, engEx Platform, to design, engineer, and manufacture exosome therapeutics. Its lead product candidates are exoSTING and exoIL-12 for the treatment of various solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CDAK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CDAK ($0.81) is undervalued by 71.85% relative to our estimate of its Fair Value price of $2.86 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CDAK ($0.81) is significantly undervalued by 71.85% relative to our estimate of its Fair Value price of $2.86 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CDAK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CDAK due diligence checks available for Premium users.
Be the first to know about important CDAK news, forecast changes, insider trades & much more!
CDAK News
Valuation
CDAK fair value
Fair Value of CDAK stock based on Discounted Cash Flow (DCF)
Price
$0.81
Fair Value
$2.86
Undervalued by
71.72%
CDAK ($0.81) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CDAK ($0.81) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CDAK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CDAK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.26x
Industry
10.7x
Market
15.09x
CDAK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.76x
Industry
5.11x
CDAK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CDAK's financial health
Profit margin
Revenue
$522.0k
Net Income
-$19.3M
Profit Margin
-3,693.1%
CDAK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CDAK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$134.4M
Liabilities
$95.5M
Debt to equity
2.45
CDAK's short-term assets ($61.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDAK's long-term liabilities ($81.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDAK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.1M
Investing
-$9.0k
Financing
$20.1M
CDAK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CDAK vs Biotech Stocks
Codiak Biosciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.